China Drug Delivery Devices Investment Opportunities

Analysis and Forecasts to 2012

Product Code GMD07527
Publication Date September 2008
Publisher Global Markets Direct
Product Type Report
Pages 142
ISBN Number not applicable
Change currency
PDF £1,895.00 €2,282 $2,996 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

China Drug Delivery Devices Investment Opportunities

Analysis and Forecasts to 2012

This report is an essential source for in-depth information and data relating to the China drug delivery devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the drug delivery devices in China

Scope

  • The report provides drug delivery devices information broken down into detailed categories and segments in China.
  • Total revenues, products sold, end users, and average pricing.
  • Market shares of all the key competitors.
  • Key pipeline products that are set to shape the market, broken down by sector.
  • Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
  • Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
  • Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
  • Key mergers and acquisitions, partnerships, private equity investments and IPOs.
  • Customer, hospitals and physicians data.

Reasons to buy

  • Gain a strong understanding of the drug delivery devices market in China
  • Evaluate and compare the attractiveness of the market in the country.
  • Identify growth segments and opportunities in each industry sector within the country.
  • Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
  • Analyze the competitiveness of the market in the country and identify hotspots.
  • Develop strategies based on the latest product, brand, expansion and research and development news in the country.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
  • Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Contents

  • 1 List of Tables
    • 1.2 List of Figures
  • 2 Introduction
    • 2.1 What Is This Report About?
    • 2.2 Definitions
      • 2.2.1 Drug delivery devices
        • 2.2.1.1 Needle-free Injections
        • 2.2.1.2 Inhalation Systems
        • 2.2.1.3 Infusion Systems
  • 3 Healthcare Sector Review
    • 3.1 Healthcare Expenditure
    • 3.2 Healthcare Infrastructure
      • 3.2.1 Healthcare Personnel Data
      • 3.2.2 Healthcare Facilities Data
    • 3.3 Healthcare Policy
  • 4 Drug Delivery Devices in China
    • 4.1 Drug Delivery Devices Overall Revenues (2000-2012)
    • 4.2 Drug Delivery Devices Overall Volume (2000-2012)
    • 4.3 Drug Delivery Devices Company Shares (2005-2006)
  • 5 Inhalation Systems in China
    • 5.1 Inhalation Systems Overall Revenues (2000-2012)
      • 5.1.1 Metered Dose Inhaler Devices Overall Revenues (2000-2012)
      • 5.1.2 Dry Powder Inhaler Devices Overall Revenues (2000-2012)
    • 5.2 Inhalation Systems Overall Volume (2000-2012)
      • 5.2.1 Metered Dose Inhaler Devices Overall Volume (2000-2012)
      • 5.2.2 Dry Powder Inhaler Devices Overall Volume (2000-2012)
    • 5.3 Inhalation Systems Average Price (2000-2012)
      • 5.3.1 Metered Dose Inhaler Devices Average Price (2000-2012)
      • 5.3.2 Dry Powder Inhaler Devices Average Price (2000-2012)
    • 5.4 Inhalation Systems Distribution Share (2005-2006)
    • 5.5 Inhalation Systems Company Share (2005-2006)
  • 6 Infusion Systems in China
    • 6.1 Infusion Systems Overall Revenues (2000-2012)
      • 6.1.1 Infusion Disposable Sets Overall Revenue (2000-2012)
      • 6.1.2 Syringe Pumps Overall Revenue (2000-2012)
      • 6.1.3 Infusion Pumps Overall Revenues (2000-2012)
    • 6.2 Infusion Systems Overall Volume (2000-2012)
      • 6.2.1 Infusion Disposable Sets Overall Volume (2000-2012)
      • 6.2.2 Syringe Pumps Overall Volume (2000-2012)
      • 6.2.3 Infusion Pumps Overall Volume (2000-2012)
    • 6.3 Infusion Systems Average Price (2000-2012)
      • 6.3.1 Infusion Pumps Average Price (2000-2012)
      • 6.3.2 Syringe Pumps Average Price (2000-2012)
      • 6.3.3 Infusion Disposable Sets Average Price (2000-2012)
    • 6.4 Infusion Systems Distribution Share (2005-2006)
    • 6.5 Infusion Systems Company Share (2005-2006)
  • 7 AstraZeneca PLC Company Profile
    • 7.1 Company Overview
    • 7.2 Business Overview
      • 7.2.1 Products
      • 7.2.2 History
    • 7.3 Locations And Subsidiaries
  • 8 3M Company Profile
    • 8.1 Company Overview
    • 8.2 Business Overview
      • 8.2.1 Consumer and Office
        • 8.2.1.1 Overview
        • 8.2.1.2 Capital Expenditure
        • 8.2.1.3 Market View
        • 8.2.1.4 Key Strategies
      • 8.2.2 Display and Graphics
        • 8.2.2.1 Overview
        • 8.2.2.2 Financials
        • 8.2.2.3 Capital Expenditure
        • 8.2.2.4 Market View
        • 8.2.2.5 Key Strategies
      • 8.2.3 Electro and Communications
        • 8.2.3.1 Overview
        • 8.2.3.2 Financials
        • 8.2.3.3 Capital Expenditure
        • 8.2.3.4 Market View
        • 8.2.3.5 Key Strategies
      • 8.2.4 Health Care
        • 8.2.4.1 Overview
        • 8.2.4.2 Financials
        • 8.2.4.3 Capital Expenditure
        • 8.2.4.4 Market View
        • 8.2.4.5 Key Strategies
      • 8.2.5 Industrial and Transportation
        • 8.2.5.1 Overview
        • 8.2.5.2 Financials
        • 8.2.5.3 Capital Expenditure
        • 8.2.5.4 Market View
        • 8.2.5.5 Key Strategies
      • 8.2.6 Safety, Security and Protection Services
        • 8.2.6.1 Overview
        • 8.2.6.2 Financials
        • 8.2.6.3 Capital Expenditure
        • 8.2.6.4 Market View
        • 8.2.6.5 Key Strategies
      • 8.2.7 Products
    • 8.3 Value Chain Analysis
      • 8.3.1 Manufacturing
        • 8.3.1.1 In House Manufacturing
      • 8.3.2 Product Development
        • 8.3.2.1 Regulatory Approvals
        • 8.3.2.2 Clinical Trials
        • 8.3.2.3 Research and Development
      • 8.3.3 Sales and Marketing
        • 8.3.3.1 Partnerships and Alliances
        • 8.3.3.2 Licensing Agreements
        • 8.3.3.3 E-distribution
    • 8.4 SWOT Analysis
      • 8.4.1 3M Company Strengths
        • 8.4.1.1 Strong performance of Industrial and Transportation segment
        • 8.4.1.2 Focused research and development
        • 8.4.1.3 Decentralized operations
  • 3M Company Weaknesses
    • 8.4.1.4 Increased operating costs in the U.S
      • 8.4.1.5 Personal care segments poor performance
  • 3M Company Opportunities
    • 8.4.1.6 Expanding global presence
      • 8.4.1.7 The liquid crystal display
      • 8.4.1.8 Enhancing brand portfolio
  • 3M Company Threats
    • 8.4.1.9 Foreign currency fluctuations
      • 8.4.1.10 Increasing cost of raw materials
      • 8.4.1.11 Trend for private labels
    • 8.5 Revenue Analysis
      • 8.5.1 Revenue by Segment
      • 8.5.2 Revenue by Geography
    • 8.6 Financial and Operational Review
      • 8.6.1 Financial Statements
      • 8.6.2 Financial Ratios
    • 8.7 Locations And Subsidiaries
  • 9 Baxter International Company Profile
    • 9.1 Company Overview
    • 9.2 Business Overview
      • 9.2.1 BioScience
        • 9.2.1.1 Overview
        • 9.2.1.2 Financials
        • 9.2.1.3 Capital Expenditure
      • 9.2.2 Medication Delivery
        • 9.2.2.1 Overview
        • 9.2.2.2 Financials
        • 9.2.2.3 Capital Expenditure
      • 9.2.3 Renal
        • 9.2.3.1 Overview
        • 9.2.3.2 Financials
        • 9.2.3.3 Capital Expenditure
      • 9.2.4 Products
      • 9.2.5 History
    • 9.3 Value Chain Analysis
      • 9.3.1 Manufacturing
        • 9.3.1.1 In House Manufacturing
      • 9.3.2 Product Development
        • 9.3.2.1 Regulatory Approvals
        • 9.3.2.2 Clinical Trials
        • 9.3.2.3 Research and Development
      • 9.3.3 Sales and Marketing
        • 9.3.3.1 Partnerships and Alliances
    • 9.4 SWOT Analysis
      • 9.4.1 Baxter International Inc. Strengths
        • 9.4.1.1 Diversified geographic presence
        • 9.4.1.2 Sturdy research and development activities
        • 9.4.1.3 Strong financial performance
      • 9.4.2 Baxter International Inc. Weaknesses
        • 9.4.2.1 High levels of inventory
        • 9.4.2.2 Decline in revenues of medication delivery
        • 9.4.2.3 Reduced capital expenditure
      • 9.4.3 Baxter International Inc. Opportunities
        • 9.4.3.1 Co-developing alliances
        • 9.4.3.2 Increasing End Stage Renal Disease patients
        • 9.4.3.3 FDA approval
      • 9.4.4 Baxter International Inc. Threats
        • 9.4.4.1 Legal proceedings
        • 9.4.4.2 Patent litigation
        • 9.4.4.3 Stringent regulations
    • 9.5 Revenue Analysis
      • 9.5.1 Revenue by Segment
      • 9.5.2 Revenue by Geography
    • 9.6 Financial and Operational Review
      • 9.6.1 Financial Statements
      • 9.6.2 Financial Ratios
    • 9.7 Locations And Subsidiaries
    • 9.8 Baxter International Inc. Pipeline Products
      • 9.8.1 Next-Generation Home Hemodialysis Machine
        • 9.8.1.1 Product Overview
        • 9.8.1.2 Product Description
        • 9.8.1.3 Product Status
        • 9.8.1.4 Product Milestone
  • 10 GlaxoSmithKline plc Company Profile
    • 10.1 Company Overview
    • 10.2 Business Overview
      • 10.2.1 Products
      • 10.2.2 History
    • 10.3 Locations And Subsidiaries
  • 11 Novartis AG Company Profile
    • 11.1 Company Overview
    • 11.2 Business Overview
      • 11.2.1 Major Products and Services
    • 11.3 Locations And Subsidiaries
  • 12 Regulation System
    • 12.1 Medical Equipment Approval Process
      • 12.1.1 Classification
      • 12.1.2 Registration and Conformity assessment
      • 12.1.3 China Compulsory Certificate (CCC Mark)
      • 12.1.4 Labeling and Packaging
      • 12.1.5 Registration Fee
      • 12.1.6 Registration Period
    • 12.2 Post Market Surveillance (PMS)
  • 13 Pricing and Reimbursement
  • 14 Distribution Structure
  • 15 Recent Developments
    • 15.1 Strategy And Business Planning
      • 15.1.1 Jul 28, 2008: Mingyuan Enters Strategic Co-Operation Memorandum With GE (CHINA)
      • 15.1.2 Apr 08, 2008: BD Opens New Manufacturing Facility In Suzhou, China
  • 16 Appendix
    • 16.1 Global Markets Direct Research Methodology
    • 16.2 Coverage
    • 16.3 Secondary Research
    • 16.4 Primary Research
    • 16.5 Models
    • 16.6 Forecasts
    • 16.7 Expert Panels
    • 16.8 Currency Conversion
    • 16.9 Contact Us
    • 16.10 Disclaimer
  • 1 List of Tables
    • Table 1: Doctors by Specialty in China, 2003-2007
    • Table 2: Hospital Wards by Specialty in China, 2003 - 2007
    • Table 3: Healthcare Institutions in China, 2000-2004
    • Table 4: Personnel Employed in Healthcare Institutions in China, 2000-2004
    • Table 5: Healthcare Institutions, Hospital Beds and Employed Personnel by Region in China, 2004
    • Table 6: Drug Delivery Devices, China, Overall Revenues ($ mn), 2000-2012
    • Table 7: Drug Delivery Devices, China, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 8: Drug Delivery Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 9: Drug Delivery Devices, China, Category Revenues ($ mn), 2000-2012
    • Table 10: Drug Delivery Devices, China, Category Revenues ($ mn), Historic, 2000-2007
    • Table 11: Drug Delivery Devices, China, Category Revenues ($ mn), Forecast, 2007-2012
    • Table 12: Drug Delivery Devices, China, Category Volume (Units), 2000-2012
    • Table 13: Drug Delivery Devices, China, Category Volume (Units), Historic, 2000-2007
    • Table 14: Drug Delivery Devices, China, Category Volume (Units), Forecast, 2007-2012
    • Table 15: Drug Delivery Devices, China, Company Share by Revenue ($ mn), 2005-2006
    • Table 16: Inhalation Systems, China, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 17: Inhalation Systems, China, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 18: Inhalation Systems, China, Revenue by Segment ($ mn), Historic, 2000-2007
    • Table 19: Inhalation Systems, China, Revenue by Segment ($ mn), Forecast, 2007-2012
    • Table 20: Metered Dose Inhaler Devices, China, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 21: Metered Dose Inhaler Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 22: Dry Powder Inhaler Devices, China, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 23: Dry Powder Inhaler Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 24: Inhalation Systems, China, Overall Volume (Units), Historic, 2000-2007
    • Table 25: Inhalation Systems, China, Overall Volume (Units), Forecast, 2007-2012
    • Table 26: Metered Dose Inhaler Devices, China, Overall Volume (Units), Historic, 2000-2007
    • Table 27: Metered Dose Inhaler Devices, China, Overall Volume (Units), Forecast, 2007-2012
    • Table 28: Dry Powder Inhaler Devices, China, Overall Volume (Units), Historic, 2000-2007
    • Table 29: Dry Powder Inhaler Devices, China, Overall Volume (Units), Forecast, 2007-2012
    • Table 30: Metered Dose Inhaler Devices, China, Average Price ($), Historic, 2000-2007
    • Table 31: Metered Dose Inhaler Devices, China, Average Price ($), Forecast, 2007-2012
    • Table 32: Dry Powder Inhaler Devices, China, Average Price ($), Historic, 2000-2007
    • Table 33: Dry Powder Inhaler Devices, China, Average Price ($), Forecast, 2007-2012
    • Table 34: Inhalation Systems, China, Distribution Share by Revenue ($ mn), 2005-2006
    • Table 35: Inhalation Systems, China, Company Share by Revenue ($ mn), 2005-2006
    • Table 36: Infusion Systems, China, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 37: Infusion Systems, China, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 38: Infusion Systems, China, Revenue by Segment ($ mn), Historic, 2000-2007
    • Table 39: Infusion Systems, China, Revenue by Segment ($ mn), Forecast, 2007-2012
    • Table 40: Infusion Disposable Sets, China, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 41: Infusion Disposable Sets, China, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 42: Syringe Pumps, China, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 43: Syringe Pumps, China, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 44: Infusion Pumps, China, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 45: Infusion Pumps, China, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 46: Infusion Systems, China, Overall Volume (Units), Historic, 2000-2007
    • Table 47: Infusion Systems, China, Overall Volume (Units), Forecast, 2007-2012
    • Table 48: Infusion Disposable Sets, China, Overall Volume (Units), Historic, 2000-2007
    • Table 49: Infusion Disposable Sets, China, Overall Volume (Units), Forecast, 2007-2012
    • Table 50: Syringe Pumps, China, Overall Volume (Units), Historic, 2000-2007
    • Table 51: Syringe Pumps, China, Overall Volume (Units), Forecast, 2007-2012
    • Table 52: Infusion Pumps, China, Overall Volume (Units), Historic, 2000-2007
    • Table 53: Infusion Pumps, China, Overall Volume (Units), Forecast, 2007-2012
    • Table 54: Infusion Pumps, China, Average Price ($), Historic, 2000-2007
    • Table 55: Infusion Pumps, China, Average Price ($), Forecast, 2007-2012
    • Table 56: Syringe Pumps, China, Average Price ($), Historic, 2000-2007
    • Table 57: Syringe Pumps, China, Average Price ($), Forecast, 2007-2012
    • Table 58: Infusion Disposable Sets, China, Average Price ($), Historic, 2000-2007
    • Table 59: Infusion Disposable Sets, China, Average Price ($), Forecast, 2007-2012
    • Table 60: Infusion Systems, China, Distribution Share by Revenue ($ mn), 2005-2006
    • Table 61: Infusion Systems, China, Company Share by Revenue ($ mn), 2005-2006
    • Table 62: AstraZeneca PLC, Subsidiaries
    • Table 63: AstraZeneca PLC, Subsidiaries(Contd..)
    • Table 64: 3M Company, SWOT Analysis, 2006
    • Table 65: 3M Company, Revenue by Segment, USD Million, 2003-2007
    • Table 66: 3M Company, Revenue by Geography, USD Million, 2003-2007
    • Table 67: 3M Company, Financial Statements, USD Million, 2003-2007
    • Table 68: 3M Company, Financial Ratios, USD Million, 2003-2007
    • Table 69: 3M Company, Subsidiaries
    • Table 70: Baxter International Inc., SWOT Analysis, 2006
    • Table 71: Baxter International Inc., Revenue by Segment, USD Million, 2003-2007
    • Table 72: Baxter International Inc., Revenue by Geography, USD Million, 2003-2007
    • Table 73: Baxter International Inc., Financial Statements, USD Million, 2003-2007
    • Table 74: Baxter International Inc., Financial Ratios, USD Million, 2003-2007
    • Table 75: Baxter International Inc., Other Locations
    • Table 76: Baxter International Inc., Subsidiaries
    • Table 77: GlaxoSmithKline plc, Subsidiaries
    • Table 78: GlaxoSmithKline plc, Subsidiaries(Contd..)
    • Table 79: Novartis Medical Nutrition, Other Locations
    • Table 80: Novartis Medical Nutrition, Other Locations(Contd..)
    • Table 81: Currency Conversion from USD to Local Currency at 2007 Constant Rate
    • 1.2 List of Figures
    • Figure 1: Total Healthcare Expenditure in China, 2000 2005
    • Figure 2: Drug Delivery Devices, China, Overall Revenues ($ mn), 2000-2012
    • Figure 3: Drug Delivery Devices, China, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 4: Drug Delivery Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 5: Drug Delivery Devices, China, Category Revenues ($ mn), 2000-2012
    • Figure 6: Drug Delivery Devices, China, Category Revenues ($ mn), Historic, 2000-2007
    • Figure 7: Drug Delivery Devices, China, Category Revenues ($ mn), Forecast, 2007-2012
    • Figure 8: Drug Delivery Devices, China, Category Volume (Units), 2000-2012
    • Figure 9: Drug Delivery Devices, China, Category Volume (Units), Historic, 2000-2007
    • Figure 10: Drug Delivery Devices, China, Category Volume (Units), Forecast, 2007-2012
    • Figure 11: Drug Delivery Devices, China, Company Share (%), 2006
    • Figure 12: Inhalation Systems, China, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 13: Inhalation Systems, China, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 14: Inhalation Systems, China, Revenue by Segment ($ mn), Historic, 2000-2007
    • Figure 15: Inhalation Systems, China, Revenue by Segment ($ mn), Forecast, 2007-2012
    • Figure 16: Metered Dose Inhaler Devices, China, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 17: Metered Dose Inhaler Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 18: Dry Powder Inhaler Devices, China, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 19: Dry Powder Inhaler Devices, China, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 20: Inhalation Systems, China, Overall Volume (Units), Historic, 2000-2007
    • Figure 21: Inhalation Systems, China, Overall Volume (Units), Forecast, 2007-2012
    • Figure 22: Metered Dose Inhaler Devices, China, Overall Volume (Units), Historic, 2000-2007
    • Figure 23: Metered Dose Inhaler Devices, China, Overall Volume (Units), Forecast, 2007-2012
    • Figure 24: Dry Powder Inhaler Devices, China, Overall Volume (Units), Historic, 2000-2007
    • Figure 25: Dry Powder Inhaler Devices, China, Overall Volume (Units), Forecast, 2007-2012
    • Figure 26: Metered Dose Inhaler Devices, China, Average Price ($), Historic, 2000-2007
    • Figure 27: Metered Dose Inhaler Devices, China, Average Price ($), Forecast, 2007-2012
    • Figure 28: Dry Powder Inhaler Devices, China, Average Price ($), Historic, 2000-2007
    • Figure 29: Dry Powder Inhaler Devices, China, Average Price ($), Forecast, 2007-2012
    • Figure 30: Inhalation Systems, China, Distribution Share (%), 2006
    • Figure 31: Inhalation Systems, China, Company Share (%), 2006
    • Figure 32: Infusion Systems, China, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 33: Infusion Systems, China, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 34: Infusion Systems, China, Revenue by Segment ($ mn), Historic, 2000-2007
    • Figure 35: Infusion Systems, China, Revenue by Segment ($ mn), Forecast, 2007-2012
    • Figure 36: Infusion Disposable Sets, China, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 37: Infusion Disposable Sets, China, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 38: Syringe Pumps, China, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 39: Syringe Pumps, China, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 40: Infusion Pumps, China, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 41: Infusion Pumps, China, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 42: Infusion Disposable Sets, China, Overall Volume (Units), Historic, 2000-2007
    • Figure 43: Infusion Disposable Sets, China, Overall Volume (Units), Forecast, 2007-2012
    • Figure 44: Syringe Pumps, China, Overall Volume (Units), Historic, 2000-2007
    • Figure 45: Syringe Pumps, China, Overall Volume (Units), Forecast, 2007-2012
    • Figure 46: Infusion Pumps, China, Overall Volume (Units), Historic, 2000-2007
    • Figure 47: Infusion Pumps, China, Overall Volume (Units), Forecast, 2007-2012
    • Figure 48: Infusion Pumps, China, Average Price ($), Historic, 2000-2007
    • Figure 49: Infusion Pumps, China, Average Price ($), Forecast, 2007-2012
    • Figure 50: Syringe Pumps, China, Average Price ($), Historic, 2000-2007
    • Figure 51: Syringe Pumps, China, Average Price ($), Forecast, 2007-2012
    • Figure 52: Infusion Disposable Sets, China, Average Price ($), Historic, 2000-2007
    • Figure 53: Infusion Disposable Sets, China, Average Price ($), Forecast, 2007-2012
    • Figure 54: Infusion Systems, China, Distribution Share (%), 2006
    • Figure 55: Infusion Systems, China, Company Share (%), 2006
    • Figure 56: 3M Company, Value Chain Analysis
    • Figure 57: Baxter International Inc., Value Chain Analysis
    • Figure 58: Medical Equipment Registration Process in China, 2007
    • Figure 59: CCC Mark Certification Process in China, 2007
    • Figure 60: Global Markets Direct Methodology